Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), filed a Form 4 on November 4, 2026 disclosing a series of transactions in the company's common stock executed on November 2, 2026.
Key Highlights
- Option exercise: LaRosa exercised a non-qualified stock option covering 12,283 shares of common stock at an exercise price of $381.92 per share on November 2, 2026.
- Tax withholding disposition: 8,686 shares were disposed of under transaction code F at $950.50 per share on the same date.
- Open-market sales: 3,939 shares were sold at a volume-weighted average price of $965.41 (ranging from $965.00 to $965.99), and 527 shares were sold at a volume-weighted average price of $966.11 (ranging from $966.00 to $966.32).
- Direct ownership after transactions: LaRosa directly held 38,906 shares of common stock following all reported transactions.
- Indirect holdings: An additional 5,407 shares are held indirectly through a 2025 GRAT, and 413 shares through a 401(k) plan.
- Option fully exercised: The non-qualified stock option, which had an expiration date of December 16, 2026, was fully exercised, leaving zero derivative securities remaining.
Regeneron EVP LaRosa Exercises Expiring Option and Sells Shares on November 2
According to the filing, Joseph J. LaRosa, who serves as Executive Vice President, General Counsel and Secretary of Regeneron Pharmaceuticals, Inc., reported four distinct transactions in the company's common stock, all occurring on November 2, 2026. The filing was submitted on November 4, 2026 and covers only transactions made by LaRosa as a single reporting person.
The filing discloses that LaRosa first exercised a non-qualified stock option to acquire 12,283 shares at a conversion price of $381.92 per share (transaction code M). The option, which had vested in four equal annual installments commencing one year after the grant date, carried an expiration date of December 16, 2026 and had zero remaining balance following the exercise. Separately, 8,686 shares were disposed of at $950.50 per share under code F, which the filing indicates as shares withheld or paid to cover a tax obligation associated with the exercise.
In addition to the option-related activity, the filing reports two open-market sales. A total of 3,939 shares were sold at a volume-weighted average price of $965.41, with individual sale prices ranging from $965.00 to $965.99. A further 527 shares were sold at a volume-weighted average price of $966.11, with prices ranging from $966.00 to $966.32. The filing notes that full information on the number of shares sold at each separate price will be provided upon request by the Commission staff, the company, or a security holder. Following all transactions, LaRosa's direct beneficial ownership stood at 38,906 shares, with an additional 5,407 shares held indirectly through a 2025 GRAT and 413 shares through a 401(k) plan.
What Was Disclosed
The Form 4 filed by Regeneron EVP Joseph J. LaRosa on November 4, 2026 discloses the exercise of 12,283 stock options and subsequent open-market sales of common stock on November 2, 2026, resulting in direct beneficial ownership of 38,906 shares.



Please wait processing your request...